Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 243Squamous Cell Carcinoma of Head and Neck 137Melanoma 137Parkinson Disease 4, Autosomal Dominant Lewy Body 119Neoplasm Metastasis 105Triple Negative Breast Neoplasms 96Neoplasms 90Lung Neoplasms 88Breast Neoplasms 79Colorectal Neoplasms 70Carcinoma, Renal Cell 69Head and Neck Neoplasms 59Urinary Bladder Neoplasms 50Stomach Neoplasms 48Ovarian Neoplasms 46Endometrial Neoplasms 45Carcinoma, Transitional Cell 44Carcinoma, Hepatocellular 35Uterine Cervical Neoplasms 34Pancreatic Neoplasms 34Esophageal Neoplasms 27Recurrence 25Prostatic Neoplasms 25Carcinoma, Squamous Cell 25Carcinoma 25Sarcoma 24Brain Neoplasms 23Glioblastoma 22Hodgkin Disease 19Cholangiocarcinoma 19

Interventions

Docetaxel 2Cisplatin 2130-nm albumin-bound paclitaxel 2taxane 1pembrolizumab 1liposomal doxorubicin 1durvalumab 1cemiplimab 1atezolizumab 1Pemetrexed 1Paclitaxel 1Nivolumab 1Granulocyte-Macrophage Colony-Stimulating Factor 1Biosimilar Pharmaceuticals 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vaccinia × pembrolizumab × 1 year × Clear all
NCT04725331 2025-11-21

A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors

Transgene

Phase 1/2 Terminated
31 enrolled
BreastDermatologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Sarcoma, Vaccinia, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡